Identification of a 14-Gene Set that Predicts Anticancer Activity of Inhibitors of the RAF/MEK/MAPK Pathway


Summary of Invention

Genetic profiling of tumors is an effective approach to cancer treatment. There is an unmet need in this field to better understand the genetic profile of different classes of tumors in an effort to tailor the therapy to suit individual needs.

The present invention provides identification of a gene expression profile that predicts the anticancer activity of inhibitors of the RAF/MEK/MAPK pathway. This technology could be used for qualifying the cancer status and response in patients, for monitoring the efficacy of a chemotherapeutic regimen and for screening new compounds


  • Excellent prognostic indicator in improving patient outcomes
  • Sensitive detection of anti-tumor response
  • Potential to tailor individual treatment regimen
  • Screening tool for new compounds
  • Novel therapeutic targets

Areas of Application

Therapeutic, prognostic, and research tool

Lead Inventors

Neal Rosen, MD, PhD, Laboratory Head, Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering

Patent Information

U.S. patent issued: 7,812,143


Contact Information:

Imke Ehlers, PhD, CLP
Senior Licensing Manager

Stage of Development

Animal studies